Top-News

SolarBank: Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte(Anzeige)

Eine Wissenschaftlerin prüft eine rote Pille (Symbolbild).

Montag, 29.08.2022 08:00 von PR Newswire | Aufrufe: 136

AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress

Eine Wissenschaftlerin prüft eine rote Pille (Symbolbild). © scanrail / iStock / Getty Images Plus / Getty Images http://www.gettyimages.de/

PR Newswire

NORTH CHICAGO, Ill., Aug. 29, 2022

Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI^® (risankizumab) in moderate to severe psoriasis and active psoriatic arthritis
Presentations include data from the largest-of-its-kind study that demonstrates the real-world burden of atopic dermatitis
Breadth of data underscores AbbVie's commitment to advancing research in dermatology for people living with immune-mediated skin diseases such as psoriasis, psoriatic arthritis, atopic dermatitis and vitiligo

NORTH CHICAGO, Ill., Aug. 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 23 abstracts at the 31^st European Academy of Dermatology and Venereology (EADV) Congress, including a late-breaking oral presentation on long-term efficacy and safety data of SKYRIZI^® (risankizumab) in psoriatic arthritis and real-world data from MEASURE-AD to assess the multidimensional burden of atopic dermatitis. This research demonstrates AbbVie's commitment to deepening the understanding of immune-mediated skin diseases by investing in studies of difficult-to-treat patient populations, certain disease areas with few existing treatment options as well as real-world patient experience. The hybrid congress will take place from September 7-10, in Milan, as well as virtually.

"Our leadership in dermatology runs deep – from developing innovative technologies to studying lesser-understood diseases where few to no treatment options currently exist," said Chiedzo Mpofu, MBChB, Ph.D., vice president, Global Medical Affairs, Immunology, AbbVie. "At this year's EADV Congress, we're presenting a range of data, including real-world, patient-centered research that will help elevate the community's understanding of the long-term impact of our treatments and the potential to support patients with difficult-to-treat diseases."

Key data to be presented include:

Late-breaking oral presentation of new data from the ongoing Phase 3 active psoriatic arthritis clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating long-term efficacy and safety, up to 100 weeks, in patients treated with SKYRIZI (risankizumab)
Analyses from MEASURE-AD, a cross-sectional, 28-country, burden of disease study aimed to characterize global treatment patterns, healthcare resource utilization and costs, and the clinical and economic burden of moderate to severe atopic dermatitis
Results from VALUE, a 13-month interim analysis from a long-term, prospective observational study that has enrolled 2,700 patients from 21 countries, evaluating real-world efficacy, durability of response and time to first treatment change for moderate to severe psoriasis patients treated with SKYRIZI (risankizumab) compared to other commonly used treatments
Results from aIMM, a Phase 3b, multicenter, interventional, open-label, single-arm study analyzing clinical efficacy, safety and quality-of-life outcomes after 16 weeks of treatment with SKYRIZI (risankizumab) in psoriasis patients who previously achieved suboptimal responses to one of two IL-17 inhibitors, either secukinumab or ixekizumab
Interim analysis of the nearly 5-year (256 weeks) LIMMitless open-label extension study evaluating long-term efficacy and safety data with continuous SKYRIZI (risankizumab) treatment in patients with moderate to severe plaque psoriasis
Two real-world insurance claims database analyses examining economic and comorbidity impacts on patients with vitiligo

AbbVie abstracts at the EADV Congress include:

Abstract Title

Session Details (All Times CEST)

Risankizumab / Psoriasis

ARIVA.DE Börsen-Geflüster

Weiter abwärts?

Kurzfristig positionieren in AbbVie Inc.
VM7VL2	Ask: 1,40	Hebel: 20,07
mit starkem Hebel		Zum Produkt
VM9RFF	Ask: 2,83	Hebel: 6,56
mit moderatem Hebel		Zum Produkt

Vontobel

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: VM7VL2,VM9RFF,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.

Kurse

AbbVie Inc.

155,52 €

-0,84%

Efficacy of Risankizumab in Psoriasis Patients Participating in the VALUE
Multi-Country Post-Marking Observational Study

Poster Session

P1538

Wednesday, Sept 7

7:00 a.m.

Efficacy and Safety of Risankizumab in Psoriasis Patients Who Had a
Suboptimal Response to Secukinumab or Ixekizumab

Poster Session

P1537

Wednesday, Sept 7

7:00 a.m.

Long-Term Safety and Efficacy of Risankizumab for the Treatment of
Moderate to Severe Plaque Psoriasis: A 4.5-year Interim Analysis of the
LIMMitless Open-Label Extension Trial

Poster Session

P1603

Wednesday, Sept 7

7:00 a.m.

Efficacy and Safety of Long-Term Risankizumab Treatment for Nail, Scalp,
and Palmoplantar Psoriasis: A 4.5-Year Interim Analysis from the LIMMitless
Open-Label Extension Trial

Poster Session

P1551

Wednesday, Sept 7

7:00 a.m.

Efficacy of Risankizumab for Moderate to Severe Plaque Psoriasis Through
256 Weeks: Subgroup Analysis by Baseline Demographics and Disease
Characteristics from the LIMMitless Trial

Poster Session

P1553

Wednesday, Sept 7

7:00 a.m.

Real-World Switching and Discontinuation Patterns for Interleukin-Inhibitor
Treatments in Patients with Moderate to Severe Psoriasis in Japan

Poster Session

P1558

Wednesday, Sept 7

7:00 a.m.

Dose Escalation of Biologic Treatment in Patients with Moderate to Severe
Psoriasis in Japan

Poster Session

P1606

Wednesday, Sept 7

7:00 a.m.

Real-World Achievement of Absolute Psoriasis Area and Severity Index
Thresholds with Risankizumab in Patients with Moderate to Severe Psoriasis
From the CorEvitas Psoriasis Registry

Poster Session

P1557

Wednesday, Sept 7

7:00 a.m.

Risankizumab / Psoriatic Arthritis

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week
Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials

Late-breaking News Session

D3T01.1

Saturday, Sept 10
9:15 - 9:30 a.m.

Durability of Clinically Meaningful Improvements in Patient-Reported
Outcomes and Work Productivity Among Patients with Psoriatic Arthritis
Receiving Risankizumab: Results from KEEPsAKE 1 and 2

Poster Session

P1429

Wednesday, Sept 7

7:00 a.m.

Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the
Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials

Poster Session

P1605

Wednesday, Sept 7

7:00 a.m.

Risankizumab (RZB) Demonstrates Long-term Efficacy Across Subgroups in
Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis
from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies

Poster Session

P1545

Wednesday, Sept 7

7:00 a.m.

Risankizumab Long-Term Safety in Patients with Psoriatic Disease: Integrated
Analyses of Data from Psoriasis and Psoriatic Arthritis Clinical Trials

Poster Session

P1607

Wednesday, Sept 7

7:00 a.m.

Efficacy Analysis in Patients with Active Psoriatic Arthritis and Significant
Involvement of Skin Manifestations

Poster Session

P1568

Wednesday, Sept 7

7:00 a.m.

Upadacitinib / Atopic Dermatitis

Efficacy of Upadacitinib vs Dupilumab for Moderate to Severe Atopic
Dermatitis: Analysis of Time Spent in Response State from the Heads Up Study

Poster Session

P0256

Wednesday, Sept 7

7:00 a.m.

Effect of Upadacitinib on Cutaneous Transcriptomic and Systemic Proteomic
Dysregulation in Patients with Moderate to Severe Atopic Dermatitis

Free Communications in Atopic Dermatitis Session

FC03.02

Thursday, Sept 8

14:25 - 14:35 p.m.

Efficacy and Safety of Upadacitinib with Topical Corticosteroids for the
Treatment of Atopic Dermatitis in Japan: 2-Year Interim Results from the
Phase 3 Rising Up Study

Free Communications in Atopic Dermatitis Session

FC03.05

Thursday, Sept 8

14:55 - 15:05 p.m.

Disease State Abstracts: Psoriasis

Epidemiologic Survey on Prevalence of Genital Psoriasis and Its Impact on
Patients' Sexual Life in Routine Care

Poster Session

P1564

Mehr Nachrichten zur AbbVie Inc. Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.